Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received a consensus rating of “Hold” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $5.8333.

ZNTL has been the subject of a number of research analyst reports. Guggenheim boosted their target price on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, April 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Tuesday, April 7th. Wells Fargo & Company began coverage on Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They set an “equal weight” rating and a $5.00 price objective for the company. Finally, Wall Street Zen lowered Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th.

Institutional Trading of Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZNTL. Sivia Capital Partners LLC bought a new stake in Zentalis Pharmaceuticals during the 4th quarter worth approximately $27,000. Qube Research & Technologies Ltd purchased a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter worth approximately $37,000. Voleon Capital Management LP purchased a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter worth approximately $41,000. SG Americas Securities LLC boosted its stake in shares of Zentalis Pharmaceuticals by 35.3% in the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after buying an additional 8,236 shares during the last quarter. Finally, Algert Global LLC purchased a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter worth approximately $73,000.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock opened at $4.28 on Friday. Zentalis Pharmaceuticals has a one year low of $1.13 and a one year high of $6.95. The firm has a market capitalization of $304.69 million, a price-to-earnings ratio of -2.25 and a beta of 1.99. The business has a 50-day simple moving average of $3.40 and a 200 day simple moving average of $2.45.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). On average, sell-side analysts expect that Zentalis Pharmaceuticals will post -1.94 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.